NIH/NIDA. Higher doses of buprenorphine may improve treatment outcomes for people with opioid use disorder
NIH/NIDA. Higher doses of buprenorphine may improve treatment outcomes for people with opioid use disorder
NIH-funded analysis suggests higher doses of buprenorphine were associated with lower rates of future behavioral health-related emergency department and inpatient care
(…) The recommended target dose for buprenorphine in the U.S. Food and Drug Administration (FDA)’s approved labeling is 16 mg per day. Researchers found that those taking higher daily doses of buprenorphine (>16 to 24 mg) took 20% longer to have a subsequent emergency department or inpatient health care visit related to behavioral health within the first year after receiving treatment, compared to those receiving >8 to 16 mg a day. Those taking daily doses of more than 24 mg of buprenorphine went 50% longer before having a subsequent emergency or inpatient health care visit related to behavioral health within the first year after receiving treatment, compared to those receiving >8 to 16 mg a day. (NIH-NIDA, USA, 25.09.2024)
https://nida.nih.gov/news-events/news-releases/2024/09/higher-doses-of-buprenorphine-may-improve-treatment-outcomes-for-people-with-opioid-use-disorder